更昔洛韦联合思密达治疗轮状病毒肠炎56例效果分析

将收治的轮状病毒肠炎婴幼儿120例随机分为2组,对照组64例,使用更昔洛韦5～10mg/(kg·d)静脉滴注;观察组56例,更昔洛韦5～10 mg/(kg·d)静脉滴注,同时口服思密达,每次1/3包,3次/d。治疗后,对照组和观察组总有效率分别为62.50%(40/64)和89.29%(50/56),差异有统计学意义(P<0.05)。表明更昔洛韦联合思密达治疗婴幼儿轮状病毒肠炎疗效显著,值得推广。     

婴幼儿体外循环心脏手术中奥美拉唑对胃肠道保护作用的临床观察

目的探讨奥美拉唑对婴幼儿体外循环（CPB）心脏手术中胃肠道的保护作用。方法45例在CPB下行先心病手术患儿,（年龄≤3岁）随机分为3组:实验A组在CPB预充液中即给予奥美拉唑10 mg,实验B组于CPB结束时给予奥美拉唑10 mg,对照组注入等量生理盐水。3组均于术前、CPB 30 m in、CPB结束后、术后4 h、24 h进行胃液常规检查,并采集血液标本,ELISA法测定血清促胃液素。结果与CPB前比较:A组胃液pH于CPB结束后有明显升高,B组胃液pH于术后4 h有明显升高,C组胃液pH变化不明显。A、B、C 3组胃液红细胞计数及血清促胃液素与本组CPB前相比均有明显上升。与对照组（C组）相比:A组胃液pH于CPB结束后各时间点较对照组明显上升,而胃液红细胞计数则有明显下降,血清促胃液素于CPB 3 m in后较对照组有明显降低。B组胃液pH于术后4、24 h较对照组有明显升高,同时间点胃液红细胞计数与促胃液素则有明显降低。结论在CPB心脏手术中预充液中即加入奥美拉唑对胃肠道有明显的保护作用。     

非淤胆型婴儿巨细胞病毒性肝炎治疗68例

目的:探讨非淤胆型婴儿巨细胞病毒性肝炎的治疗方法.方法:选择2008-01/2010-07本院儿科住院的68例非淤胆型婴儿巨细胞病毒性肝炎患儿,随机分为治疗组34例和对照组34例,均予复方甘草酸苷2 mL/(kg.次),1次/d,共3 wk.治疗组加用更昔洛韦5 mg/(kg.次),2次/d,2 wk;1次/d,1 wk.结果:治疗组和对照组总有效率分别为94.1%和91.1%,治疗3 wk复查肝功能指标结果提示丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(total bilirubin,T B I L)、谷氨酰转肽酶(g a m m a g l u t a m y ltranspeptidase,GGT)和碱性磷酸酶(alkalinephosphatase,ALP)指标较治疗前均明显下降,差异有显著意义(P<0.05);直接胆红素(directbilirubin,DBIL)、总胆汁酸(total bile acid,TBA)指标较治疗前均无明显变化,差异无显著意义(P>0.05).治疗前或治疗后2组间比较上述指标差异无显著意义(P>0.05).随访1年,失访5人,余患儿肝功能均正常;尿CMV-DNA,治疗组18人(54.5%)阳性,对照组15人(50.0%)阳性,差异无显著意义(P>0.05).结论:非淤胆型婴儿巨细胞病毒性肝炎不建议常规予更昔洛韦抗病毒治疗.     

The effect of glucose control on clinical outcomes of correction surgery in infants with hyperglycemia and congenital heart disease

Background Currently it remains controversial whether intensive control of glucose is required for pediatric hyperglycemia. Few studies are available on the blood glucose control for the infants receiving congenital heart disease operation. However, there are no uniform standards to control hyperglycemmia after congenital heart disease operation. In this study, we determined the ranges and methods of postoperative blood glycemic control in infants with congenital heart disease. Methods Eighty-two infants younger than 6 months of age,who underwent correction of congenital heart disease in our hospital from 06/01/2014 to 06/01/2015, participated in this study. All patients were randomly divided into two groups: group A(insulin control group) and group B(non-insulin control group). Each group was randomly divided into three subgroups(A1-A3.B1-B3).Children in group A were treated using the glycemic control therapy with insulin. Children in group B received a glycemic control therapy without insulin. Femoral vein blood was drew in 72 hours after the operation to check WBC, CRP, lactate, ALT and Cr. The duration of ICU, incidence of lung infection, hypoglycemia and mortality were recorded. Results The differences of Cr ALT, WBC and CRP indexes were statistically significant(P 0.05) in A and B subgroups, but not between the A and B groups(P 0.05). The ICU stay time of group A2 and B2 was less than that of other groups, but the difference was not statistically significant(P 0.05). The incidence of pulmonary infection and hypoglycemia in 2 groups was lower than that in A1 and A3 group. The incidence of complications in group B2 was lower than that in B1 group and B3 group, but there was no significant difference(P 0.05). There was no significant difference between the A and B groups(P 0.05). Conclusions Hyperglycemia can increase postoperative pulmonary infection. Aggressive control of blood glucose does not improve patient outcomes, but increases the incidence of hypoglycemia.     

Effect of oral ibuprofen on patent ductus arteriosus in premature newborns

Background aim of the studyPatent ductus arteriosus (PDA), a common finding among premature infants, is conventionally treated by intravenous indomethacin. Intravenous ibuprofen was recently shown to be as effective and to have fewer adverse reactions in preterm infants. If equally effective, then oral ibuprofen for PDA closure would have several important advantages over the intravenous route. This study was designed to determine whether oral ibuprofen treatment is efficacious and safe in closure of a PDA in premature infants.Patients and methodsThirty-three premature group I (study group) were treated with ibuprofen 10 mg/kg administered through a feeding tube. Thirty-three premature group II (control group) receive placebo the two imaging procedures were again performed 24 h after each ibuprofen dose. When the PDA was still hemodynamically significant, as demonstrated by echocardiography, and there was no evidence of deterioration in brain ultrasonography, a second dose of ibuprofen 5 mg/kg (placebo for control) was administered. A third equivalent dose was given after another 24 h if necessary. Cranial ultrasound was repeated 1 week after the last ibuprofen dose and again before discharge from the ward. Hematochemical analysis was preformed daily in the unit during the first days of life.ResultsIn the study group the rate of PDA closure was 93.9% (31 of 33 cases) while in the control group the rate of PDA closure was 30.3% (10 of 33 cases) with significant difference in between. There was no reopening of the ductus after closure had been achieved. No infant required surgical ligation of the ductus in study group while in the control group 24.2% (8 of 33 cases) were required surgical ligation (Table 2). Twenty-one newborns were treated with 1 dose of ibuprofen, 9 were treated with 2 doses, and the remaining 3 were treated with 3 doses.ConclusionOral ibuprofen is an effective and safe alternative to intravenous ibuprofen for PDA closure in premature infants.     

The effect of different glucose control schemes on clinical outcomes of congenital heart disease in infants under age of 6 months

Background It remains controversial whether intensive control of glucose is required for pediatric hyperglycemia and no consensus has been reached on the threshold for blood glucose control for perioperative pediatric patients. Few studies have been available on the blood glucose control for the infants receiving congenital heart disease operation. So far, there are no uniform standards to control hyperglycemmia after congenital heart disease operation. In this paper, we determined the ranges and methods of postoperative blood glycemic control in infants with congenital heart disease. Methods Eighty-two infants under 6 months of age, who underwent correction of congenital heart disease in our hospital from 06/01/2014 to 06/01/2015, participated in this study. All patients were randomly divided into two groups according to random number table method: group A(insulin control group) and group B(non-insulin control group). Each group was furhter divided into three subgroups(A1-A3, B1-B3). Children in group A were treated using the glycemic control therapy with insulin. Children in group B received a glycemic control therapy without insulin. Femoral vein blood was drew in 72 hours after the operation to check WBC,CRP,lactate,ALT and Cr. The duration of ICU, incidence of lung infection, incidence of hypoglycemia, and mortality were measured and computed. Results The differences of Cr,ALT, WBC and CRP index between A and B subgroups were statistically significant(P 0.05). There were no significant differences in ALT, Cr, WBC and CRP levels between the A and B groups(P 0.05). The stay time of ICU in group A2 was significantly less than that in A1 or A3 group. ICU stay time was significantly less in group B2 than in B1 or B3 group. The incidence of pulmonary infection and hypoglycemia in 2 groups were lower than those in A1 and A3 group. There was no significant difference(P 0.05) in the incidence of complications in B subgroups and between the two groups. Conclusions High blood sugar can increase postoperative pulmonary infection. Aggressive control of blood sugar does not improve patient outcomes, but increases the incidence of hypoglycemia.     

布地奈德雾化吸入治疗婴幼儿喘息的疗效观察

目的观察布地奈德雾化吸入治疗婴幼儿喘息的疗效。方法 103例轻中度喘息婴幼儿分为治疗组50例、对照组53例,综合治疗的基础上治疗组予布地奈德雾化吸入治疗,缓解后逐渐减量吸入,对照组主要采用静脉滴注甲强龙治疗,咳喘缓解后改泼尼松口服。观察治疗后咳嗽、哮鸣音消失所需天数、本次喘息的经济费用、家长误工时间,3月随访期内反复喘息发作例数等。结果两组急性期咳嗽及哮鸣音消失时间、平均费用上比较差异无统计学意义(P>0.05)。治疗组家长误工天数较对照组有明显的差异(P<0.05)。三个月内喘息反复的例数两组比较差异无统计学意义(P>0.05)。结论对于婴幼儿喘息,布地奈德雾化吸入相对全身静脉使用糖皮质激素简易方便、患者安全。     

Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report

Previously healthy infants less than 6 months of age with severe respiratory syncytial virus bronchiolitis who required hospitalization were identified from hospital records. Infants had been treated either conservatively (control group, n = 19) or with ribavirin added to conservative management (study group, n = 22). All infants underwent a 1-year follow-up after the initial illness. There was a significant reduction in the prevalence of reactive airway disease in the group treated with ribavirin (P < 0.05) compared with the control group, both in terms of the proportion of patients developing airway reactivity (59% vs. 89%) and the number of episodes of reactive airway disease (31 vs. 70). Our data suggest that ribavirin reduces the prevalence of airway reactivity. Pediatr. Pulmonol. 1998; 25:154–158. © 1998 Wiley-Liss, Inc.     

Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants

OBJECTIVE: To measure hepatic and hematological parameters among neonates randomized to receive ultra-short antiretroviral regimens. DESIGN: As part of an on-going clinical trial in Malawi, infants born to women who received (early presenters) or did not receive (late presenters) standard intrapartum nevirapine (NVP) dosing were randomized to receive orally either single dose NVP alone or NVP plus zidovudine (twice daily for 1 week). An additional group of untreated infants (born to HIV-uninfected women) was enrolled as a control. METHODS: Laboratory measurements were performed at birth and repeated at 6 weeks of age. Serum alanine aminotransferase (ALT) was measured on approximately 200 infants consecutively enrolled and randomized at the start of the trial. Complete blood count (CBC) was performed on approximately 800 infants at birth and 600 infants at 6 weeks of age. ALT and CBC were also determined on approximately 200 control infants. RESULTS: At birth there were no differences in ALT values between the groups of children. At 6 weeks of age, ALT levels were significantly higher among the treated groups compared with control group (geometric mean of 11.5 U/l for controls and 16.2-19.1 U/l for treated groups; P < 0.0001). Hematological parameters did not differ between groups at birth. At 6 weeks of age, levels of hemoglobin, hematocrit, granulocytes, and platelets were significantly (P < 0.0001) lower among antiviral drug-treated groups compared with controls. These changes were consistent with grade 1 (mild) toxicity, and were more noticeable among HIV-infected infants. CONCLUSIONS: Hepatic and hematologic abnormalities associated with short-term neonatal antiretrovirals among African children are minimal.     

Changes in plasma thyroid hormone levels after a single dose of triiodothyronine in premature infants of less than 30 weeks gestational age

OBJECTIVE: Evaluation of thyroid hormone response to a single administration of triiodothyronine (T3) early postnatally to premature infants of <30 weeks gestational age. DESIGN: A prospective clinical trial with historical control. METHODS: Ten infants born <28 weeks gestational age and ten infants born between 28 and 30 weeks gestational age were given 0.5 microg/kg T3 intravenously at 12 h after birth. The infants <28 weeks gestational age were also treated with thyroxine (T4; 8 microg/kg, once daily) during the first 6 weeks of life. Premature infants from a previous trial served as a matched historical control group. Analysis of variance for repeated measurements was performed. RESULTS: For the infants <28-30 weeks gestational age mean plasma T3 concentrations were significantly higher in the T3-treated group (P=0.027) for at least 2 weeks, whereas mean plasma levels of T4, free T4 and TSH were comparable. For the infants <28 weeks gestational age plasma T3 levels were also significantly different after correction for gestational age (P=0.0002), with either comparable or higher values in the T3-treated infants up to 56 days after injection of T3. Mean plasma free T4 levels were lower during the first 3 days and higher or comparable thereafter (P=0.0014), and TSH suppression was more evident in the T3-treated infants (P=0.003). CONCLUSION: A single administration of T3 to premature infants <30 weeks gestational age early postnatally results in a sustained increase of plasma T3 levels during the first weeks of life. In infants of 28-30 weeks gestational age this occurs without change in plasma free T4 levels, whereas in infants <28 weeks gestational age a transient decrease of plasma free T4 was present. The increase in plasma T3 is possibly caused by a T3-induced increase of type I deiodinase activity.     

Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis

BackgroundAnatomic interventions for pulmonary vein stenosis (PVS) in infants and children have been met with limited success. Sirolimus, a mammalian target of rapamycin inhibitor, has demonstrated promise as a primary medical therapy for PVS, but the impact on patient survival is unknown.ObjectivesThe authors sought to investigate whether mTOR inhibition with sirolimus as a primary medical therapy would improve outcomes in high-risk infants and children with PVS.MethodsIn this single-center study, patients with severe PVS were considered for systemic sirolimus therapy (SST) following a strict protocol while receiving standardized surveillance and anatomic therapies. The SST cohort was compared with a contemporary control group. The primary endpoint for this study was survival. The primary safety endpoint was adverse events (AEs) related to SST.ResultsBetween 2015 and 2020, our PVS program diagnosed and treated 67 patients with ≥moderate PVS. Of these, 15 patients were treated with sirolimus, whereas the remaining patients represent the control group. There was 100% survival in the SST group compared with 45% survival in the control group (log-rank p = 0.004). A sensitivity analysis was completed to address survival bias using median time from diagnosis of PVS to SST. A survival advantage persisted (log-rank p = 0.027). Two patients on sirolimus developed treatable AEs. Patients in the SST group underwent frequent transcatheter interventions with 3.7 catheterizations per person-year (25th to 75th percentile: 2.7 to 4.4 person-years). Median follow up time was 2.2 years (25th to 75th percentile: 1.2 to 2.9 years) in the SST group versus 0.9 years (25th to 75th percentile: 0.5 to 2.7 years) in the control group.ConclusionsThe authors found a survival benefit associated with SST in infants and children with moderate-to-severe PVS. This survival benefit persisted after adjusting the analysis for survival bias. There were 2 mild AEs associated with SST during the study period; both patients were able to resume therapy without recurrence.     

肺表面活性物质预防早产儿呼吸窘迫综合症的临床观察

目的对肺表面活性物质固尔苏应用于早产儿呼吸窘迫综合症的早期预防效果进行观察及分析。方法选取早产儿病例120例,根据患儿家长意愿分组为固尔苏组62例和对照组58例。在常规进行心电监测、入恒温箱、抗感染等治疗基础上,对照组不应用固尔苏,固尔苏组给予固尔苏用药治疗。结果固尔苏组患儿的平均通气时间、氧疗时间和住院时间明显短于对照组(P0.01);固尔苏组患儿呼吸机相关性肺炎、肺气漏和视网膜病变发病率明显低于对照组(P0.05);固尔苏组患儿治愈率明显高于对照组,致死率和NRDS发生率明显低于对照组(P0.01)。结论肺表面活性物质预防早产儿呼吸窘迫综合症具有较好的疗效,可快速改善患儿肺功能、提高肺顺应性,并且降低并发症的发生以及致死率。     

布地奈德联合硫酸特布他林氧驱动雾化吸入佐治婴幼儿毛细支气管炎疗效分析简

目的 观察布地奈德和硫酸特布他林联合雾化吸入治疗婴幼儿毛细支气管炎的疗效.方法 选择2011年2月至2013年3月住院治疗的毛细支气管炎患儿80例,随机分为治疗组和对照组各40例,两组患儿均予平喘、祛痰、抗感染,必要时吸氧等综合治疗.治疗组在综合治疗基础上加用布地奈德联合硫酸特布他林氧驱雾化吸入,对照组在综合治疗基础上加用DXM联合糜蛋白酶超声雾化吸入.结果 治疗组在喘憋缓解时间,咳嗽缓解时间,肺部体征改善时间,呼吸困难缓解时间有效率等方面均优于对照组,两组比较差异有统计学意义（P〈0.05）.结论 布地奈德联合硫酸特布他林氧驱动雾化吸入佐治毛细支气管炎,症状、体征缓解快,有效率高,可作为毛细支气管炎治疗重要手段.     

Clinical characteristics of neonatal infants born to mothers with pulmonary tuberculosis

Three hundred and seventy neonatal infants born by mothers with pulmonary tuberculosis were examined. A control group comprised 121 neonatal babies born by apparently healthy women. The infants born by ill mothers weighed less. In the study group, 142 (38.4%) babies with asphyxia were born. In infants born by mothers with active tuberculosis, birth asphyxia was observed 1.5 times as frequently as in those born by healthy mothers. In the control group, only 11 (9.1%) children with mild asphyxia were born. Neonatal compilations were noted in 137 (37.1%) infants of the study group, moreover almost equally frequently in babies born by mothers with both active and inactive tuberculosis, they were in 12 (9.9%) babies in the control group. In the latter group, malformations were detected only in 2 (1.7%) newborn babies, in the study one, they were in 46 (12.4%) infants, the mothers of these 15 (32.6%) infants had received specific therapy for tuberculosis in early pregnancy.     

Follow-up examination at the age of 15 months of extremely preterm infants after postnatal estradiol and progesterone replacement

A randomized controlled pilot study was performed with a sample of extremely preterm infants to evaluate the impact of postnatal estradiol and progesterone replacement on postnatal bone mineral accretion. Twenty-five of 30 infants in the pilot study survived, and of these, 24 infants were available for the follow-up examination at a median chronological age of 18.1 months (minimum-maximum, 17.0--20.6) corresponding to a corrected age of 14.8 months (minimum-maximum, 12.9--17.4). Somatic growth data and bone mineralization showed no differences between the hormone-treated and control group infants. The deviation of the skeletal age from the corrected age was 0.0 months (minimum-maximum, -7.7 to 7.4) for hormone-treated infants compared with -1.7 months (minimum-maximum, -7.5 to 5.9) for the control group. The Bayley scales mental and psychomotor developmental indexes were 89 (minimum-maximum, 71--107) and 101 (minimum-maximum, 49--121) for the hormone-treated infants and 93 (minimum-maximum, 49--111) and 71 (minimum-maximum, 49--121) for the control group infants, respectively (mental developmental index, P = 1.0; psychomotor developmental index, P = 0.14). The normal psychomotor development in the hormone-treated infants compared with the below average development in the control group infants is encouraging and indicates the potentially important integrative role of sex steroids for the developing brain. Larger studies on the effects of the postnatal replacement of estradiol and progesterone in extremely preterm infants are warranted.     

不同用药方法阻断艾滋病母婴传播73例临床观察

目的 观察不同用药方法 阻断艾滋病母婴传播效果.方法 2005~2007年应用维乐命方案(方案1)阻断HIV母婴传播26例,2008~2010年联合应用三联抗病毒药物方案(方案2)阻断HIV母婴传播47例.所出生的婴儿均采用人工喂养,随访观察至18月龄.结果 两种方案出生的婴儿外观均未见畸形,方案1出现2例婴儿HIV阳性(母儿均服药及仅婴儿服药各1例);方案2出现1例婴儿HIV阳性(仅婴儿服药),母儿均服药均为阴性.结论 对HIV阳性孕妇采取综合干预措施(抗病毒药物治疗、婴儿人工喂养)能有效阻断HIV母婴传播.     

痰热清注射液辅助治疗小儿肺炎的临床观察

目的观察痰热清注射液辅助治疗小儿肺炎的临床效果。方法对我院收住的118例肺炎患儿随机分为治疗组和对照组各59例,对照组常规应用抗感染、抗病毒、退热、止咳化痰、吸氧、改善微循环及营养支持等综合治疗,治疗组在常规治疗基础上加用痰热清注射液,qd,疗程5～10 d。结果治疗组总愈显率93.22%,总有效率98.31%;对照组总愈显率74.58%,总有效率88.14%,2组总愈显率和总有效率比较差异有统计学意义(P<0.05);治疗组在临床症状消失、体征明显改善、肺部阴影吸收、WBC计数恢复正常及总疗程等方面与对照组比较,差异有统计学意义(P<0.001)。结论痰热清注射液辅助治疗小儿肺炎,能较快控制病情、改善呼吸道症状和体征、恢复正常体温,缩短疗程。其使用安全,临床疗效确切。     

Protective efficacy of plasma-derived hepatitis beta vaccine in preventing perinatal transmission of HBV infection in infants of HBsAg/HBeAg positive mothers

Two hundred and four newborn infants of HBsAg/HBeAg carrier mothers were randomly assigned into three groups. Group A (69 infants) received full-dose HB vaccine, group B (70 infants) received half-dose HB vaccine at birth, 1 month, 3 months and group C (65 infants) were untreated control group. After twelve months follow-up the cumulative incidence of HBs antigenemia was 17.2%, 30% in group A, B respectively as compared with 78.4% in group C (p less than 0.001). The protective efficacy rates (PER) of group A and B were 78.1% and 61.7% respectively (p less than 0.05). The vaccine was also effective in preventing persistent HBsAg carriers (HBsAg positive for at least 6 months). The PER of group A and B were at least 74.9% and 49.2% respectively (p less than 0.001) at 1 year follow-up. From the practical point of view and economic reasons administration of full-dose HB vaccine give better protection to high risk infants.     

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study

Summary. This randomized, double‐blind, placebo‐controlled study evaluated whether lamivudine given during late pregnancy can reduce hepatitis B virus (HBV) perinatal transmission in highly viraemic mothers. Mothers were randomized to either lamivudine 100 mg or placebo from week 32 of gestation to week 4 postpartum. At birth, infants received recombinant HBV vaccine with or without HBIg and were followed until week 52. One hundred and fifty mothers, with a gestational age of 26–30 weeks and serum HBV DNA >1000 MEq/mL (bDNA assay), were treated. A total of 141 infants received immunoprophylaxis at birth. In lamivudine‐treated mothers, 56 infants received vaccine + HBIg (lamivudine + vaccine + HBIg) and 26 infants received vaccine (lamivudine + vaccine). In placebo‐treated mothers, 59 infants received vaccine + HBIg (placebo + vaccine + HBIg). At week 52, in the primary analyses where missing data was counted as failures, infants in the lamivudine + vaccine + HBIg group had a significant decrease in incidence of HBsAg seropositivity (10/56, 18%vs 23/59, 39%; P = 0.014) and in detectable HBV DNA (11/56, 20%vs 27/59, 46%; P = 0.003) compared to infants in the placebo + vaccine + HBIg group. Sensitivity analyses to evaluate the impact of missing data at week 52 resulting from a high dropout rate (13% in the lamivudine + vaccine + HBIg group and 31% in the placebo + vaccine + HBIg group) remained consistent with the primary analysis in that lower transmission rates were still observed in the infants of lamivudine‐treated mothers, but the differences were not statistically significant. No safety concerns were noted in the lamivudine‐treated mothers or their infants. Results of this study suggest that lamivudine reduced HBV transmission from highly viraemic mothers to their infants who received passive/active immunization.     

一氧化碳(CO)吸入疗法在足月新生儿肺炎中应用的安全性以及抗炎、抗氧化作用

目的评价在足月新生儿肺炎患儿中应用一氧化碳(CO)吸入疗法的有效性及安全性。方法对我院近年收治的80例新生儿肺炎患儿进行随机对照分组,对照组(n=40)采用常规抗感染、祛痰止咳等方案,治疗组(n=40)在对照组治疗方案基础上加用CO吸入疗法,比较两组患儿抗炎、抗氧化指标及不良反应情况。结果治疗组与对照组临床总有效率分别为95.0%、92.5%,组间比较并无明显差异(χ~2=2.024,P0.05),但治疗组显效率(57.5%)明显高于对照组显效率(42.5%)(χ~2=8.774,P0.05),两组患者治疗2h、5 h后丙二醛(MDA)、血清晚期氧化蛋白产物(AOPPs)水平比较并无明显改变(P0.05),治疗组总抗氧化能力(TAOC)、巨噬细胞炎症蛋白-2(MIP-2)水平较治疗前下降明显(P0.05),且与同期对照组比较也有明显差异(P0.05)。结论 CO吸入疗法佐治足月新生儿肺炎可有效改善炎症及应激状态,且安全性较高,值得推广应用。